TXN and rheumatoid arthritis: As Tregalizumab interacts with CD4+ CD25+ Tregs,31 which secrete high amounts of Trx1, it can be speculated that Trx1 might also negatively impact the binding and signalling of Tregalizumab in the synovium of RA patients.